Multi-targeted, aggressive drug therapies needed for complete response, remission of this lupus complication
Search results for: cardiovascular risk
Hydrocodone Bitartrate, Secukinumab, Varenicline Updates, Trials, Approvals
Plus, rheumatology drug news, safety updates
Gout, Glucose Metabolism and Obesity: A Case Review
New research explores association between hyperurecimia and gout with metabolic derangement
Rheumatology Research Foundation’s Annual Investigators’ Meeting Spotlights Latest Findings
Groundbreaking research in treatments for rheumatoid arthritis, inflammatory disease discussed at Foundation’s celebrated event
Recipients of Ephraim P. Engleman Endowed Resident Research Preceptorship Award in Rheumatology Meet Physician Who Helped Shape Their Careers
Award’s namesake, 103-year-old rheumatologist Ephraim P. Engleman, MD, met 10 winners of research funding established in his name by the Rheumatology Research Foundation in 2006
Rheumatology Drug Updates, Trials, Safety Data
Information on acetaminophen restrictions; trials for clazakizumab, epratuzumab, romosozumab; and drug safety updates rheumatologists need to know
Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch
Rheumatology Research Foundation Advances Studies in Inflammatory Arthritis
Disease Targeted Research Initiative may improve treatment, prevention of rheumatoid arthritis, other inflammatory diseases
ACR/ARHP Annual Meeting 2012: How to Manage Gout Effectively in the Context of Comorbid Conditions
Comorbid conditions such as chronic kidney disease and cardiovascular disease can complicate gout management, but effective treatment and preventive strategies are available
EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Advances in the rheumatology clinic are promising, two experts say.
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 56
- Next Page »